Steve Hyman directs the Stanley Center for Psychiatric Research of the Broad Institute of Harvard and MIT, creating a bridge between HSCRB and the center. The Stanley Center focuses on schizophrenia, bipolar disorder, autism spectrum disorders (ASDs), and frequently co-occurring neurodevelopmental disorders, including attention deficit hyperactivity disorder (ADHD).
Hyman does not have an individual lab, but has offices both at 7 Divinity Ave. on Harvard's main campus and at the Broad Institute.
Steven Hyman, M.D.
- Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology
Stanley Center for Psychiatric Research at the Broad Institute
- Core Institute Member
Broad Institute of MIT and Harvard
- Principal Faculty
Harvard Stem Cell Institute
Steven E. Hyman, M.D., is a Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology and a Core Institute Member of the Broad Institute of Harvard and MIT, where he directs the Stanley Center for Psychiatric Research. The Stanley Center engages in large-scale, globally conducted studies of neuropsychiatric genetics, stem cell biology, neurobiology, and technology development in support of translational efforts focused on reducing the global burden of psychiatric disorders.
Hyman also serves as chair of the board of Charles A. Dana Foundation, which supports research and education in neuroscience. In addition, he is a Director of the Charles H. Revson Foundation, of the Wyss Center for Bio and Neuroengineering (Geneva, Switzerland) and of the nonprofit scientific publisher Annual Reviews Inc. In the private sector, he is a Director of Voyager Therapeutics and Q-State Biosciences and serves on the scientific advisory boards of Janssen Pharmaceuticals, BlackThorn Therapeutics, and F-Prime Capital.
From 2001 to 2011 Hyman served as Provost of Harvard University, the university’s chief academic officer. From 1996 to 2001, he served as Director of the U.S. National Institute of Mental Health (NIMH), where he emphasized investment in neuroscience and emerging genetic technologies. He also initiated a series of large practical clinical trials to inform practice.
Hyman has served as President of the Society for Neuroscience (2015), President of the American College of Neuropsychopharmacology (2018), founding President of the International Neuroethics Society (2008-2013), and Editor of the Annual Review of Neuroscience (2002-2016). He is a fellow of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science, and a member of the National Academy of Medicine, where he served on the governing Council (2012-2018) and which he represented on the Governing Board of the National Research Council, the operating arm of the US National Academies of Sciences, Engineering, and Medicine (2016-2019). From 2012-2018 Hyman chaired the Forum on Neuroscience and Nervous System Disorders of the US National Academies, which brings together industry, government, foundations, patient groups, and academia. In 2016, he was awarded the Rhoda and Bernard Sarnat International Prize in Mental Health by the National Academy of Medicine.
Hyman received his B.A., summa cum laude, from Yale College, an M.A. from the University of Cambridge, which he attended as a Mellon fellow studying History and Philosophy of Science, and an M.D., cum laude, from Harvard Medical School.
The Stanley Center is making significant advances in understanding molecular mechanisms of neuropsychiatric diseases as a critical step toward discovering effective new therapeutics. Its focus areas are schizophrenia, bipolar disorder, autism spectrum disorders (ASDs), and frequently co-occurring neurodevelopmental disorders, including attention deficit hyperactivity disorder (ADHD).
Stanley Center researchers work on these illnesses because of their public health significance and because their high heritability has made them tractable to modern genomic and computational tools. We study these disorders together because they exhibit informative patterns of shared genetic risk and because their pathogenesis occurs against the backdrop of brain development.
Within the Center there are robust interactions among scientist focused on genetics, neurobiology based both in stem cell technologies and animal models, therapeutic discovery, and epidemiology. Stanley Center members share a commitment to interdisciplinary exchange and sharing of methods, tools, and data, with the goal of bringing the most effective tools to bear as rapidly as possible on the difficult scientific problems of mental illness. We collaborate extensively with research groups around the world to identify important patient populations, technologies, and scientific approaches that will significantly advance our research objectives and knowledge for the psychiatric research community.